When venture capital firms invest in private companies and publicly listed companies in sectors like pharmaceuticals, biotechnology, and medical devices, which questions need to be considered and addressed in advance to ensure successful exit transactions? Experts will discuss in a panel their experiences when establishing exit strategies.
Schellenberg Wittmer is a top-tier full-service Swiss law firm with offices in Zurich, Geneva and Singapore whose team of over 160 lawyers provide a comprehensive range of legal services to a worldwide client base. The firm's Life Sciences Group is a leading practice for transactional work, dispute resolution and regulatory matters, advising and representing companies from a variety of sectors, including pharma, biotechnology, medical devices, cosmetics and food and beverages.
